SBIR-STTR Award

Single cell tri-omics: High coverage simultaneous profiling of DNA, RNA, and proteins in single cells
Award last edited on: 3/4/2025

Sponsored Program
SBIR
Awarding Agency
NIH : NIA
Total Award Amount
$268,142
Award Phase
1
Solicitation Topic Code
853
Principal Investigator
Robin Prince

Company Information

Fluid Discovery Inc

42 Longview Drive
Daly City, CA 94015
Location: Single
Congr. District: 15
County: San Mateo

Phase I

Contract Number: 2024
Start Date: ----    Completed: 2/1/2024
Phase I year
2024
Phase I Amount
$268,142
Alzheimer's disease, a devastating neurologic disorder, accounts for 60-80% of all dementias, making the development of new technologies for studying the disease crucial. Fluid Discovery aims to advance single-cell proteomics with a groundbreaking product called Self-Assembled Partitioning Proteomics (SAP-pm), which will quantify thousands of proteins in hundreds of thousands of individual cells and can be multiplexed with single cell DNA and RNA sequencing. Building on cutting-edge work in microfluidics, biophysics, and genomics, SAP- pm offers a unique, rapid, and cost-effective method to overcome limitations in protein coverage and sensitivity found in current technologies. The project comprises two aims: (1) Develop SAP-pm for sensitive, thousand-plex analysis of proteins at the single cell level, and (2) Expand the capability of SAP-pm to analyze brain nuclei and simultaneously capture mRNA, facilitating valuable insights from primary human tissues to improve human health.

Public Health Relevance Statement:
NARRATIVE Fluid Discovery aims to commercialize a single-cell proteomics approach, Self-Assembled Partitioning Proteomics (SAP-pm), for Alzheimer's research - enabling the quantification of thousands of proteins in hundreds of thousands of individual cells, while being multiplexed with DNA and RNA sequencing. This innovative approach overcomes limitations of existing technologies and allows for tri-omic profiling, shedding light on the mechanisms of proteomic dysregulation and unveiling new therapeutic targets. Terms:

Phase II

Contract Number: 1R43NS135703-01
Start Date: 1/31/2026    Completed: 00/00/00
Phase II year
----
Phase II Amount
----